Shots:

• The P-III study evaluates Medicago’s plant-based COVID-19 vaccine + GSK’s pandemic adjuvant in ~24,000 patients aged ≥18yrs. with COVID-19 across 6 countries
• The results showed a 71% overall vaccine efficacy rate against all variants of SARS-COV-2, & demonstrated 75.3% efficacy against COVID-19 of any severity for the globally dominant Delta variant while 88.6% against Gamma variant, well-tolerated & no related serious AEs were observed. The safety profile was consistent with P-II results
• Medicago plans to file a final regulatory submission with Health Canada imminently & has initiated the regulatory filing for the adjuvanted plant-based COVID-19 vaccine candidate with the US FDA & MHRA

 Ref: GSK | Image: GSK